Dr. Giorgio Scagliotti on Taking a Targeted Approach to Immunotherapy in Lung Cancer

Giorgio V. Scagliotti, MD, PhD
Published: Tuesday, Aug 30, 2016


Giorgio V. Scagliotti, MD, PhD, Professor and Chair of Medical Oncology at the University of Turin and San Luigi Hospital, Orbassano, Italy, explains why immunotherapy treatments should be used with a targeted approach in lung cancer.
 
Immunotherapy is a sort of targeted therapy, says Scagliotti. Immunotherapy needs to be integrated into precision medicine, which by default requires the identification of a target. It is likely that there are multiple targets that can be identified for use with immunotherapy.
 
A diagnostic biomarker needs to be identified to isolate the type of patient that is getting a benefit from immunotherapy, says Scagliotti.
 

Giorgio V. Scagliotti, MD, PhD, Professor and Chair of Medical Oncology at the University of Turin and San Luigi Hospital, Orbassano, Italy, explains why immunotherapy treatments should be used with a targeted approach in lung cancer.
 
Immunotherapy is a sort of targeted therapy, says Scagliotti. Immunotherapy needs to be integrated into precision medicine, which by default requires the identification of a target. It is likely that there are multiple targets that can be identified for use with immunotherapy.
 
A diagnostic biomarker needs to be identified to isolate the type of patient that is getting a benefit from immunotherapy, says Scagliotti.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x